百济神州泽布替尼胶囊启动IV期临床 适应症为初治华氏巨球蛋白血症

新浪财经
Sep 17

药物临床试验登记与信息公示平台数据显示,百济神州(苏州)生物科技有限公司的一项评价泽布替尼治疗中国初治华氏巨球蛋白血症患者的有效性和安全性的4期、单臂、开放性、多中心研究已启动。临床试验登记号为CTR20253625,首次公示信息日期为2025年9月17日。该药物剂型为胶囊,规格为120粒/瓶,80mg/粒,用法用量为160mg,一天两次,用药时程直至疾病进展、出现不可接受的毒性或死亡、撤回知情...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10